All AbMole products are for research use only, cannot be used for human consumption.
Andarine (GTX-007) is a selective nonsteroidal androgen receptor (AR) agonist with Ki of 4 nM. It is an investigational selective androgen receptor modulator (SARM) for treatment of conditions such as muscle wasting, osteoporosis and benign prostatic hypertrophy, using the non-steroidal androgen antagonist bicalutamide as a lead compound. Andarine is less potent in both anabolic and androgenic effects than other SARMs. Andarine exhibits potent and efficacious anabolic activity and results in dose-dependent stimulation of growth in prostate, seminal vesicles, and levator ani muscle with the ED50 of 0.43 mg/day, 0.55 mg/day, and 0.14 mg/day, respectively. Andarine reduced prostate weight with similar efficacy to finasteride, but without producing any reduction in muscle mass or anti-androgenic side effects. Andarine demonstrates tissue-selective pharmacological activity and significantly decreased prostate weight to 79.4% at a concentration of 0.5 mg/day in intact rats. Andarine (GTx-007) is able to competitively block binding of dihydrotestosterone to its receptor targets in the prostate gland.
| Molecular Weight | 441.36 |
| Formula | C19H18F3N3O6 |
| CAS Number | 401900-40-1 |
| Solubility (25°C) | DMSO 80 mg/mL Ethanol 80 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related Androgen Receptor Products |
|---|
| LGD-3303
LGD-3303 is a nonsteroidal, nonaromatizable selective androgen receptor ligand that binds to the androgen receptor with high affinity in a radiolabeled to competitive binding assay (Ki=0.9 nM). |
| Ar-V7-IN-1
Ar-V7-IN-1 is a potent inhibitor of Ar-V7. AR-V7 is a hormone-independent splice variant of the androgen receptor. Ar-V7-IN-1 has the potential for the research of various indications such as prostate cancer. |
| SC912
SC912 is a potent and selective AR-V7 inhibitor with IC50 of 0.36 μM. SC912 binds directly to AR-FL and AR-V7 proteins, inhibites nuclear localization and chromatin binding capabilities. SC912 exerts anticancer activity through inhibition of proliferation, induction of cell cycle arrest and apoptosis. |
| A4B17
A4B17 is an androgen receptor N-terminal inhibitor, which can be used for the research of androgen-responsive prostate cancer. |
| AZ'3137
AZ‘3137 is an orally active PROTAC-type androgen receptor (AR) degrader, with a DC50 value of 22 nM. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
